[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100375376":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":20,"studyPopulation":11,"armGroups":21,"interventions":38,"overallOfficials":11,"centralContacts":56,"locations":62,"responsibleParty":147,"collaborators":11,"id":149,"slug":11,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":150,"sex":156,"minAge":157,"maxAge":11,"enrollmentInfo":158,"targetDuration":11,"studyType":161,"phases":162,"briefSummary":164,"conditions":165,"keywords":11,"overallStatus":85,"whyStopped":11,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},{"fullName":5,"class":6},"Celyad Oncology SA","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Occurrence of Dose Limiting Toxicities as defined per protocol in order to define the final recommended dose.",null,"from start the first infusion of CYAD-02 (Day1) up to Day36.",{"allocation":14,"interventionModel":15,"interventionModelDescription":16,"primaryPurpose":17,"observationalModel":11,"timePerspective":11,"maskingInfo":18},"NON_RANDOMIZED","SEQUENTIAL","Dose escalation","TREATMENT",{"masking":19,"maskingDescription":11,"whoMasked":11},"NONE","This open-label phase I, multi-center study aims to determine in relapsed\u002Frefractory acute myeloid leukemia or myelodysplastic syndrome patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patients.\n\nDuring dose escalation, three prespecified dose-levels of CYAD-02 will be evaluated in three cohorts. Patient enrollment during dose-escalation will be staggered according to the Fibonacci 3+3 design and extension of cohorts II and III will be done in parallel. The first CYAD-02 infusion will be administered after prior non-myeloablative preconditioning chemotherapy (CYFLU) administered on three consecutive days.\n\nNon-progressive patients meeting the criteria specified below may receive a consolidation cycle with three additional CYAD-02 infusions at a 2-week interval without prior preconditioning.\n\nFor all patients who received at least one CYAD-02 infusion, the overall study duration will be approximately 15 years.",[22,30,34],{"label":23,"type":24,"description":25,"interventionNames":26},"Dose Escalation Dose Level 1","EXPERIMENTAL","in case of no dose limiting toxicity (DLT) and no replacement of patients, 3 consecutive patients at the dose of 1x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.\n\nThe preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg\u002Fm²\u002Fday) and fludarabine (30 mg\u002Fm²\u002Fday), two days before the CYAD-02 infusion.\n\nIn case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy.",[27,28,29],"Biological: CYAD-02","Drug: ENDOXAN","Drug: Fludara",{"label":31,"type":24,"description":32,"interventionNames":33},"Dose Escalation Dose Level 2","in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 3x10e8 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.\n\nThe preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg\u002Fm²\u002Fday) and fludarabine (30 mg\u002Fm²\u002Fday), two days before the CYAD-02 infusion.\n\nIn case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy.",[27,28,29],{"label":35,"type":24,"description":36,"interventionNames":37},"Dose Escalation Dose Level 3","in case of no dose limiting toxicity (DLT) and no replacement of patients,3 consecutive patients at the dose of 1x10e9 of CYAD-02 per infusion post preconditioning non-myeloablative chemotherapy according to a 3+3 study design.\n\nThe preconditioning therapy consists of 3 consecutive days of cyclophosphamide (300 mg\u002Fm²\u002Fday) and fludarabine (30 mg\u002Fm²\u002Fday), two days before the CYAD-02 infusion.\n\nIn case of no progression at D22, the patient is eligible to receive a consolidation cycle of 3 additional CYAD-02 infusion at the same dose level, without prior preconditioning chemotherapy.",[27,28,29],[39,44,51],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"BIOLOGICAL","CYAD-02","CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.",[23,31,35],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"DRUG","ENDOXAN","administered as preconditioning chemotherapy",[23,31,35],[50],"cyclophosphamide",{"type":45,"name":52,"description":47,"armGroupLabels":53,"otherNames":54},"Fludara",[23,31,35],[55],"fludarabine",[57],{"name":58,"role":59,"phone":60,"phoneExt":11,"email":61},"Frederic LEHMANN, MD, PhD","CONTACT","003210394100","flehmann@celyad.com",[63,83,99,117,132],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Mayo Clinic Cancer Center","NOT_YET_RECRUITING","Jacksonville","Florida","32224","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-81.65565,30.33218,{"lat":75,"lon":74},[78,81],{"name":79,"role":59,"phone":80,"phoneExt":11,"email":11},"Mohamed Kharfan Dabaja, MD","904-953-3376",{"name":79,"role":82,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":84,"status":85,"city":86,"state":87,"zip":88,"country":69,"countryCode":70,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"University of Kansas Cancer Center","RECRUITING","Fairway","Kansas","66205",{"type":72,"coordinates":90},[91,92],-94.6319,39.02223,{"lat":92,"lon":91},[95,98],{"name":96,"role":59,"phone":97,"phoneExt":11,"email":11},"Tara LIN, MD","913-945-5052",{"name":96,"role":82,"phone":11,"phoneExt":11,"email":11},{"facility":100,"status":85,"city":101,"state":11,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Uz Leuven","Leuven","3000","Belgium","BE",{"type":72,"coordinates":106},[107,108],4.70093,50.87959,{"lat":108,"lon":107},[111,115],{"name":112,"role":59,"phone":113,"phoneExt":11,"email":114},"Johan MAERTENS, MD","003216 34 68 80","johan.maertens@uzleuven.be",{"name":116,"role":82,"phone":11,"phoneExt":11,"email":11},"Johan MAERTENS",{"facility":118,"status":85,"city":119,"state":11,"zip":120,"country":103,"countryCode":104,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Chu Liege","Liège","4000",{"type":72,"coordinates":122},[123,124],5.56749,50.63373,{"lat":124,"lon":123},[127,131],{"name":128,"role":59,"phone":129,"phoneExt":11,"email":130},"YVES BEGUIN, MD","0032 4 242 52 00","yves.beguin@chuliege.be",{"name":128,"role":82,"phone":11,"phoneExt":11,"email":11},{"facility":133,"status":85,"city":134,"state":11,"zip":135,"country":103,"countryCode":104,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"AZ DELTA","Roeselare","8800",{"type":72,"coordinates":137},[138,139],3.12269,50.94653,{"lat":139,"lon":138},[142,146],{"name":143,"role":59,"phone":144,"phoneExt":11,"email":145},"Dries DEEREN, MD","003251 23 73 22","Dries.Deeren@azdelta.be",{"name":143,"role":82,"phone":11,"phoneExt":11,"email":11},{"type":148,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100375376",false,"NCT04167696","Study in Relapsed\u002FRefractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02","Open-label, Phase I, Multi-center Study to Determine in Relapsed\u002FRefractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle","CYCLE-1","Inclusion Criteria (main):\n\n* The patient must not be eligible for standard of care therapy and have one of the following hematological malignancy:\n\n  1. A confirmed relapsed or refractory acute AML (i.e. ≥ 5% blasts in bone marrow or in peripheral blood) with revised European LeukemiaNet (ELN) 2017 risk stratification for favorable, intermediate or adverse groups, after at least one prior therapy defined as either\n\n     * Recurrence of disease after a first complete remission and not eligible for a second course of induction therapy, or\n     * Recurrence of disease after a second complete remission, or\n     * Failure to achieve a Complete Response after induction chemotherapy.\n  2. A confirmed MDS as defined by revised International Prognostic Scoring System criteria for intermediate, high-risk or very high-risk disease or MDS with Tumor Protein 53 mutation as detected by next-generation sequencing, after failure of prior treatment with at least 4 cycles of azacitidine or decitabine defined as:\n\n     * No response to treatment,\n     * Loss of response at any time point, or\n     * Intolerance to therapy.\n* The patient must have evaluable disease as defined by:\n\n  * Revised Recommendations of the International Working Group (IWG) for Diagnosis, Standardization of Response Criteria for AML patients,\n  * IWG 2006 Uniform Response Criteria for patients with MDS.\n* The absolute peripheral blast count should be \\\u003C 15,000\u002FL.\n* The patient must have adequate hepatic and renal functions, as assessed by standard laboratory criteria.\n* The patient must have a left ventricular ejection fraction of ≥ 40 %, as determined by echocardiography or a multigated acquisition scan.\n* The patient must have a Forced Expiratory Volume (FEV) in the first second \u002FForced Vital Capacity = 0.7 with FEV-1 at 50 % predicted (GOLD 1 or 2 severity) as determined by spirometry\n\nExclusion Criteria (main):\n\n* Patients with a confirmed or history of tumor involvement in the central nervous system\n* Patients who have received any cancer therapy with therapeutic intent (investigational agent or not)\n* Patients with any positive serology test results at baseline\n* Patients who plan to receive, are concurrently receiving or have received any investigational agent within 3 weeks before the planned day for the first CYAD-02 infusion\n* Patients with uncontrolled intercurrent illness or serious uncontrolled medical disorder\n* Patients with significant coagulation disorder or who are receiving treatment with warfarin derivatives, heparin or direct oral anticoagulants\n* Patients who have active infections\n* Patients with documented history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis and\u002For active or acute exacerbation of chronic obstructive pulmonary disease","ALL","18 Years",{"count":159,"type":160},27,"ESTIMATED","INTERVENTIONAL",[163],"PHASE1","An open-label, phase I, multi-center study to determine in relapsed\u002Frefractory (r\u002Fr) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r\u002Fr AML\u002FMDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.",[166,167],"Acute Myeloid Leukemia","Myelodysplastic Syndrome","2020-06-08",{"date":170,"type":171},"2020-06-09","ACTUAL",{"date":173,"type":171},"2019-11-25",{"date":175,"type":160},"2035-02",{"name":5,"class":6},5]